WST 8-K: Q3 2025 press release and presentation furnished

Rhea-AI Filing Summary

West Pharmaceutical Services, Inc. furnished an 8-K announcing its third-quarter 2025 financial results. The company provided a press release and an investor presentation as exhibits.

The materials were furnished under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD). The company noted these items are furnished, not filed, and therefore are not subject to Section 18 liabilities. The press release (Exhibit 99.1) and presentation (Exhibit 99.2) are dated October 23, 2025.

8-K Event Classification

3 items: 2.02, 7.01, 9.01

3 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

0000105770false00001057702025-10-232025-10-23

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) – October 23, 2025

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania

1-8036

23-1210010

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

530 Herman O. West Drive, Exton, PA

19341-1147

(Address of principal executive offices)

(Zip Code)

 Registrant’s telephone number, including area code: 610-594-2900

Not Applicable

(Former name or address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol			Name of each exchange on which registered
Common Stock, par value $0.25 per share			WST			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

Item 2.02 Results of Operations and Financial Condition.

On October 23, 2025, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing its third-quarter 2025 financial results. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7.01 Regulation FD Disclosure.

The information set forth in “Item 2.02 Results of Operations and Financial Condition,” including the exhibit referred to therein, is incorporated herein by reference.

A copy of the Company’s presentation materials used during the call will be available through the Investors link at the Company’s website, http://www.westpharma.com, and is also attached hereto as Exhibit 99.2 and incorporated herein by reference.

The information in this report (including the exhibits attached hereto) is being furnished pursuant to Item 2.02 and Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific referencing in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)			Exhibit No.			Description
			99.1			West Pharmaceutical Services, Inc. Press Release, dated October 23, 2025.
			99.2			West Pharmaceutical Services, Inc. Presentation, dated October 23, 2025.
			104			The cover page from the Company’s Current Report on Form 8-K, dated October 23, 2025, formatted in Inline XBRL.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ Robert W. McMahon

Robert W. McMahon

Senior Vice President, Chief Financial Officer

October 23, 2025

3

EXHIBIT INDEX

Exhibit No.						Description
99.1						West Pharmaceutical Services, Inc. Press Release, dated October 23, 2025.
99.2						West Pharmaceutical Services, Inc. Presentation, dated October 23, 2025.
104						The cover page from the Company’s Current Report on Form 8-K, dated October 23, 2025, formatted in Inline XBRL.

4

FAQ

What did WST announce in this 8-K?

The company announced its third-quarter 2025 financial results and furnished related materials.

Which exhibits accompany WST’s Q3 2025 results?

Exhibit 99.1 is the press release, and Exhibit 99.2 is the investor presentation, both dated October 23, 2025.

Under which items were the materials furnished for WST?

They were furnished under Item 2.02 (Results of Operations) and Item 7.01 (Regulation FD).

Are WST’s Q3 2025 materials deemed filed?

No. The company states the information is furnished, not filed, and not subject to Section 18 liabilities.

Where can investors find WST’s presentation?

It is available via the Investors link at westpharma.com and attached as Exhibit 99.2.

What is WST’s trading market and symbol?

Common stock trades on the NYSE under the symbol WST.